These effects are accompanied by ROS reducing potential and iNOS activity, together with improved Nrf2 and heme oxygenase-1 (HO-1) levels in various neurological disorders, such as epilepsy, Parkinson’s disease and MS [50]. This evidence concerns the gene HMOX1 and myeloid sarcoma.